FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Andrew J. Armstrong, MD, MSc, about the FDA approval of olaparib (Lynparza) plus abiraterone in patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Armstrong is a professor of medicine, a professor in surgery, and a professor of pharmacology and cancer biology, as well as a member of the Duke Cancer Institute in Durham, North Carolina.

On May 31, 2023, the FDA approved olaparib plus abiraterone and prednisone or prednisolone in patients with mCRPC harboring deleterious or suspected deleterious BRCA mutations. This regulatory decision was backed by findings from the phase 3 PROpel trial (NCT03732820), in which the median radiographic progression-free survival was not reached in patients with BRCA mutations who received the olaparib combination vs 8 months in those with BRCA mutations who received placebo plus abiraterone.

In our exclusive interview, Dr Armstrong discussed the significance of this approval, key efficacy and safety data from PROpel, and where the field of prostate cancer research may be headed in the future.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.